Phenothiazines as anti-tubercular agents: mechanistic insights and clinical implications

Bibliography

• World Health Organization. Global tuberculosis control. Geneva, Switzerland 2010. Available from: http://whqlibdoc.who.int/publications/2010/9789241564069_eng.pdf
   Google Scholar
• World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): Global report on surveillance and response. Geneva, Switzerland 2010. Available from: http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf
   Google Scholar
• Delay J, Deniker P, Harl JM. Therapeutic method derived from hibernotherapy in excitation and agitation states. Ann Med Psychol 1952;20:267-73
   Google Scholar
• Motohashi N. Thiazines and structurally-related compounds. In proceedings of the sixth international conference on phenothiazines and structurally related psychotropic compounds, Pasadona; CA. Kreiger Publishers: FL. 1992
   Google Scholar
• Motohashi N. Bioactive Molecules 4: Phenothiazines and 1,4-Benzothiazine, Chemical and Biomedical Aspects. Elsevier; Amsterdam: 1988
   Google Scholar
• Molnar J, Sakagami H, Motohashi N. Biological and chemical aspects of thiazines and analogs. Enlight Associates, San Gabriel; California: 1995
   Google Scholar
• Motohashi N, Kawase M, Saoth K, Sakagami H. Cytotoxic potential of phenothiazines. Curr Drug Targets 2006;7:1055-66
   PubMed Web of Science ®Google Scholar
• Motohashi N, Kawase M, Saito S, Sakagami H. Antitumor potential and potential targets of phenothiazine-related compounds. Curr Drug Targets 2001;1:237-45
   Google Scholar
• Motohashi N, Sakagami H, Molnar J. Non-Antibiotics: a New Class of Unrecognized Antimicrobics 1. National Institute of Science Communications (CSIR); New Delhi: 1998
   Google Scholar
• Molnar J, Foldeak S, Tanaka M, Non-Antibiotics: a New Class of Unrecognized Antimicrobics 1. National Institute of Science Communications (CSIR); New Delhi: 1998
   Google Scholar
• Zhang Y, Martens K, Denkins S. New drug candidates and therapeutic targets for tuberculosis chemotherapy. Drug Discov Today 2006;11:21-7
   PubMed Web of Science ®Google Scholar
• Steiner M. Newer and second line drugs in the treatment of drug resistant tuberculosis in children. Med Clin North Am 1967;51:1153-67
   PubMed Web of Science ®Google Scholar
• Gandhi NR, Moll A, Sturm AW, Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368:1575-80
   PubMed Web of Science ®Google Scholar
• Velayati AA, Masjedi MR, Farnia P, Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant or totally drug-resistant strains in Iran. Chest 2009;136:420-5
   PubMed Web of Science ®Google Scholar
• Yew WW, Cynamon M, Zhang Y. Emerging drugs for the treatment of tuberculosis. Expert Opin Emerg Drugs 2011;16:1-21
   PubMed Web of Science ®Google Scholar
• Neuremberger EL, Spigelman MK, Yew WW. Current development and future prospects in chemotherapy of tuberculosis. Respirology 2010;15:764-78
   PubMed Web of Science ®Google Scholar
• Yew WW, Leung CC. Management of multidrug resistant tuberculosis: update 2007. Respirology 2008;13:21-46
   PubMed Web of Science ®Google Scholar
• DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: New estimates of drug development costs. J Health Econ 2003;22:151-85
   PubMed Web of Science ®Google Scholar
• Bettencourt MV, David SB, Amaral L. Comparative in-vitro activity of phenothiazines against multidrug-resistant mycobacterium tuberculosis. Int J Antimicrob Agents 2000;16:69-71
   PubMed Web of Science ®Google Scholar
• Amaral L, Kristiansen JE, Abebe LS, Millet W. Inhibition of the respiration of multi-drug resistant clinical isolates of mycobacterium tuberculosis by thioridazine: potential use for the initial therapy of freshly diagnosed tuberculosis. J Antimicrob Chemother 1996;38:1049-53
   PubMed Web of Science ®Google Scholar
• Van Ingen J, Van der Laan T, Amaral L, In-vitro activity of thioridazine against mycobacteria. Int J Antimicrob Agents 2009;34:190-1
   PubMed Web of Science ®Google Scholar
• Bettencourt-Viveiros M, Amaral L. Enhancement of antibiotic activity against poly-drug resistant mycobacterium tuberculosis by phenothiazines. Int J Antimicrob Chemother 2001;17:225-8
   Google Scholar
• Kristiansen JE, Amaral L. The potential management of resistant infections with non-antibiotics. J Antimicrob Chemother 1997;40:319-27
   PubMed Web of Science ®Google Scholar
• Cha YY, Ong YM, Chua KL. Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. Antimicrob Agents Chemother 2007;41:623-30
   Google Scholar
• Kristiansen MM, Leondro C, Ordway D. Thioridazine reduces resistance of methicillin-resistant Staphylococcus aureus by inhibiting a reserpine sensitive efflux pump. In Vivo 2006;20:361-6
   PubMed Web of Science ®Google Scholar
• Ordway D, Viveiros M, Leandro C. Clinical concentrations of thioridazine kill intracellular multidrug-resistant mycobacterium tuberculosis. Antimicrob Agents Chemother 2003;47:917-22
   PubMed Web of Science ®Google Scholar
• Guth PS, Spirtes MA. The phenothiazine tranquilizers: Biochemical and biophysical actions. Int Rev Neurobiol 1964;7:231-78
   PubMed Web of Science ®Google Scholar
• Moriya F, Hashimoto Y. Redistribution of basic drugs into cardiac blood from surrounding tissues during early steps post-mortem. J Forensic Sci 1999;44:10-16
   PubMed Web of Science ®Google Scholar
• Crowle AJ, Douvas GS, May MH. Chlorpromazine: A drug potentially useful for treating mycobacterial infections. Chemotherapy 1992;38:410-19
   PubMed Web of Science ®Google Scholar
• Amaral L, Kristiansen JE, Molnar J. Clinical concentrations of thioridazine enhance the killing of intracellular methicillin resistant Staphylococcus aureus: an in vivo, ex vivo and electron microscopy study. In Vivo 2004;18:787-94
   PubMed Web of Science ®Google Scholar
• Van Sooligen D, Hernandez-Pando R, Orozco H, The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis. PLoS ONE 2010;5:e12640
   PubMedGoogle Scholar
• Corbett EL, Watt CJ, Walker N, The growing burden of tuberculosis: global trends and interaction with the HIV epidemic. Arch Intern Med 2003;163:1009-21
   PubMed Web of Science ®Google Scholar
• Voskuil MI, Schappinger D, Visconti KC, Inhibition of respiration by nitric oxide induces a mycobacterium tuberculosis dormancy program. J Exp Med 2003;190:705-13
   Google Scholar
• Saunders BM, Frank AA, Orme IM. Granuloma formation is required to contain bacillus growth and delay mortality in mice chronically infected with mycobacterium tuberculosis. Immunology 1999;98:324-8
   Google Scholar
• Cardona PJ, Ruiz-Manzano J. On the nature of Mycobacterium tuberculosis-latent bacilli. Eur Respir J 2004;24:1044-51
   PubMed Web of Science ®Google Scholar
• Morita RY. Starvation in bacteria. Plenum press; New York: 1993
   Google Scholar
• Ulrich T, Kaufmann SHE. Tuberculosis. Lippincott Williams and Wilkins; Philadelphia: 2004
   Google Scholar
• Brunoru M, Giuffre A, Forte E, Control of cytochrome c oxidase activity by nitric oxide. Biochim Biophys Acta 2004;1655:365-71
   PubMed Web of Science ®Google Scholar
• Lanbo S, Charles DS, Bavesh DK. Changes in the energy metabolism of mycobacterium tuberculosis in mouse lung and under in vitro conditions affecting aerobic respiration. Proc Nat Acad Sci 2005;102:15629-34
   PubMed Web of Science ®Google Scholar
• Rubin H, Lonsdale JT, Duncan K, Inhibitors of type II NADH: menaquinone oxidoreductase represent a class of antitubercular drugs. Proc Nat Acad Sci 2005;102:4548-53
   PubMed Web of Science ®Google Scholar
• Rubin H, Teh JS, Weinstein E, Steady state kinetics and inhibitory action of antitubercular phenothiazines on mycobacterium tuberculosis type II NADH-menaquinone Oxidoreductases (NDH-2). J Biol Chem 2006;281:11456-63
   PubMed Web of Science ®Google Scholar
• Kopanoff DE, Snider DE Jr, Caras CJ. Isoniazid related hepatitis: a US public health service cooperative surveillance study. Am Rev Respir Dis 1978;117:991-1001
   PubMed Web of Science ®Google Scholar
• Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. J Am Med Assoc 1999;281:1014-18
   PubMed Web of Science ®Google Scholar
• Zilber LA, Bajdakova ZL, Gardasjan AN, The prevention and treatment of isoniazid toxicity in the therapy of pulmonary tuberculosis 2. An assessment of the prophylactic effect of pyridoxine in low dosage. Bull World Health Organ 1963;29:457-81
   PubMed Web of Science ®Google Scholar
• Stout JE. Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection. Expert Opin Drug Saf 2004;3:187-98
   PubMedGoogle Scholar
• Rothfield NF, Bierer WF, Garfield JW. Isoniazid induction of antinuclear antibodies. A prospective study. Ann Intern Med 1978;88:650-2
   PubMed Web of Science ®Google Scholar
• Holdiness MR. Adverse cutaneous reactions to antituberculosis drugs. Int J Dermatol 1985;24:280-5
   PubMed Web of Science ®Google Scholar
• Horsberg CR Jr, Goldberg S, Bethel J, Latent tuberculosis infection treatment acceptance and completion in the United States and Canada. Chest 2010;137:401-9
   PubMed Web of Science ®Google Scholar
• Aspler A, Long R, Trajman A, Impact of treatment completion, intolerance and adverse events on health system costs in a randomized trial of 4 months rifampin or 9 month isoniazid for latent tuberculosis. Thorax 2010;65:582-7
   PubMed Web of Science ®Google Scholar
• Fourrier A, Gasquet I, Allicar MP, Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists. Br J Clin Pharmacol 2000;49:80-6
   PubMed Web of Science ®Google Scholar
• Garcia-Rodriguez LA, Ruigomez A, Jick H. A review of epidemiological research on drug induced acute liver injury using general practice research database in United Kingdom. Phermacother 1997;17:721-8
   PubMed Web of Science ®Google Scholar
• Keplowitz N, Aw TY, Simon FR. Drug induced hepatotoxicity. Ann Intern Med 1986;104:829-39
   Google Scholar
• Pisciotta V. Drug induced agranulocytosis. Drugs 1978;15:132-43
   PubMed Web of Science ®Google Scholar
• Jaanus SD. Ocular side effects of selected systemic drugs. Optom Clin 1992;2:73-96
   PubMedGoogle Scholar
• Chignell CF, Mothen AG, Buettner GR. Photo-induced free radicals from chlorpromazine and related phenothiazines: relationship to phenothiazine-induced photosensitization. Environ Health Perspec 1985;64:103-10
   PubMed Web of Science ®Google Scholar
• Most H. Studies on the effectiveness of phenothiazine in human nematode infections. Am J Trop Med 1943;23:459-64
   Google Scholar
• Yang SY, Kao Yang YH, Chong MY, Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study. Clin Pharmacol Ther 2007;81:586-94
   PubMed Web of Science ®Google Scholar
• Harrigan EP, Miceli J, Anziano R, A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004;24:62-9
   PubMed Web of Science ®Google Scholar
• Thomas SHL. QT interval prolongation and ventricular arrhythmias. Adverse Drug React Toxicol Rev 1994;13:77-102
   PubMedGoogle Scholar
• Hartigan-Go K, Bateman DN, Nyberg G, Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther 1996;60:543-53
   PubMed Web of Science ®Google Scholar
• Kelly HQ, Fay JE, Laverty FG. Thioridazine hydrochloride (Mellaril): its effect on the electrocardiogram and a report of two fatalities with electrocardiographic abnormalities. Can Med Assoc J 1963;89:546-54
   PubMed Web of Science ®Google Scholar
• Kilts CD, Knight DL, Mailman RB, Effects of thioridazine and its metabolites on dopaminergic function: drug metabolism as a determinant of the antidopaminergic actions of thioridazine. J Pharmacol Exp Ther 1984;231:334-42
   PubMed Web of Science ®Google Scholar
• Niedzwiecki DM, Cubeddu LX. Comparative antidopaminergic properties of thioridazine, mesoridazine and sulphoridazine on the corpus striatum. J Pharmacol Exp Ther 1989;250:117-25
   PubMed Web of Science ®Google Scholar
• Dahl SG. Active metabolites of neuroleptic drugs: possible contribution to therapeutic and toxic effects. Ther Drug Monit 1982;4:33-40
   PubMed Web of Science ®Google Scholar
• Drolet B, Vincent F, Rail J, Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. J Pharmacol Exp Ther 1999;288:1261-9
   PubMed Web of Science ®Google Scholar
• Tie H, Walker BD, Valenzuela SM, The heart of psychotropic drug therapy. Lancet 2001;355:1825
   Web of Science ®Google Scholar
• Su Z, Martin R, Cox BF, Gintant G. Mesoridazine: an open-channel blocker of human ether-a-go-go-related gene K+ channel. J Mol Cell Cardiol 2004;36:151-60
   PubMed Web of Science ®Google Scholar
• Salih IS, Thanacoody RH, McKay GA, Thomas SH. Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses. Clin Pharmacol Ther 2007;82:548-54
   PubMed Web of Science ®Google Scholar
• Thanacoody RH, Daly AK, Reilly JG, Factors affecting drug concentrations and QT interval during thioridazine therapy. Clin Pharmacol Ther 2007;82:555-65
   PubMed Web of Science ®Google Scholar
• Hale PW Jr, Poklis A. Thioridazine-5-sulphoxide cardiotoxicity in the isolated, perfused rat heart. Toxicol Lett 1984;21:1-8
   PubMed Web of Science ®Google Scholar
• Heath A, Svensson C, Martensson E. Thioridazine toxicity–an experimental cardiovascular study of thioridazine and its major metabolites in overdose. Vet Hum Toxicol 1985;27:100-5
   PubMedGoogle Scholar
• Hine B, Traficante L J, Sakalis G, Gershon S. Thioridazine and EKG anomalies. Experientia 1979;35:1631-2
   PubMedGoogle Scholar
• Thanakoody RH. Thioridazine: resurrection as an antimicrobial agent? Br J Clin Pharmcol 2007;64:566-74
   PubMed Web of Science ®Google Scholar
• Ray WA, Meredith S, Thapa PB, Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001;58:1161-7
   PubMed Web of Science ®Google Scholar
• Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes and sudden death. Am J Psychiatry 2001;158:1774-82
   PubMed Web of Science ®Google Scholar
• Salih FA, Kaushik NK, Sharma P. Calmodulin like activity in mycobacteria. Indian J Biochem Biophys 1991;28:491-5
   PubMed Web of Science ®Google Scholar
• Ratnakar P, Murthy PS. Trifluoperazine inhibits the incorporation of labeled precursors into lipids, proteins and DNA of Mycobacterium tuberculosis H37Rv. FEMS Microbiol Lett 1993;110:291-4
   PubMed Web of Science ®Google Scholar
• Motohashi N. Phenothiazines and Calmodulin. Anticancer Res 1991;11:1125-64
   PubMed Web of Science ®Google Scholar
• Sitges M, Talamo BR. Sphingosine, W-7 and trifluoperazine inhibit the elevation in cytosolic calcium induced by high K+ depolarization in synaptosomes. J Neurochem 1993;61:443-50
   PubMed Web of Science ®Google Scholar
• Choi SY, Kim YH, Lee YK, Chlorpromazine inhibits store-operated calcium entry and subsequent noradrenaline secretion in PC12 cells. Br J Pharmacol 2001;132:411-18
   PubMed Web of Science ®Google Scholar
• Khan SZ, Longland CL, Michelangeli F. The effect of phenothiazines and other calmodulin antagonists on the sarcoplasmic and endoplasmic reticulum Ca2+ pumps. Biochem Pharmacol 2000;60:1797-806
   PubMed Web of Science ®Google Scholar
• Sand O, Sletholt K, Gautvik KM, Haug E. Trifluoperazine blocks calcium-dependent action potentials and inhibits hormone release from rat pituitary tumor cells. Eur J Pharmacol 1982;86:177-84
   PubMed Web of Science ®Google Scholar
• Filburn CR, Colpo FT, Sacktor B. Mechanism of phenothiazine inhibition of Ca2+ dependent guanosine 3′, 5′-(cyclic) monophosphate phosphodiesterase of brain. Mol Pharmacol 1979;15:257-62
   PubMed Web of Science ®Google Scholar
• Perez RP, Handel LM, Hamilton TC. Potentiation of cisplatin cytotoxicity in human ovarian carcinoma cell lines by trifluoperazine, a calcium inhibitor. Gynecol Oncol 1992;46:82-7
   PubMed Web of Science ®Google Scholar
• Charp PA, Regan JD. Inhibition of DNA repair by trifluoperazine. Biochim Biophys Acta 1985;824:34-9
   PubMed Web of Science ®Google Scholar
• Charp PA. DNA repair in human cells; Methods for the determination of calmodulin involvements. Methods Enzymol 1987;139:715-30
   PubMed Web of Science ®Google Scholar
• Malik ZA, Denning GM, Kusner DJ. Inhibition of Ca2+ signaling by mycobacterium tuberculosis is associated with decreased phagosome lysosome fusion and increased survival within human macrophages. J Exp Med 2000;191:287-91
   PubMed Web of Science ®Google Scholar
• Sudeshna G, Parimal K. Multiple non-psychiatric effects of phenothiazines: a review. Eur J Pharmacol 2010;648:6-14
   PubMed Web of Science ®Google Scholar
• Perskvist N, Zheng L, Stendahl O. Activation of human neutrophils by Mycobacterium tuberculosis H37Ra involves phospholipase Cg2, Shc adaptor protein, and p38 mitogen activated protein kinase. J Immunol 2000;164:959-65
   PubMed Web of Science ®Google Scholar
• Roach SK, Schorey JS. Differential regulation of the mitogen-activated protein kinases by pathogenic and nonpathogenic mycobacteria. Infect Immun 2002;70:3040-52
   PubMed Web of Science ®Google Scholar
• Ordway D, Viveiros M, Leandro C. Intracellular activities of clinical concentrations of phenothiazines including thioridazine against phagocytosed staphylococcus aureus. Int J Antimicrob Agents 2002;20:34-43
   PubMed Web of Science ®Google Scholar
• Ordway D, Viveiros M, Leandro C. Chlorpromazine has intracellular killing activity against phagocytosed staphylococous aureus at clinical concentrations. J Infect Chemother 2002;8:227-31
   PubMedGoogle Scholar
• Hendrich AB, Motohashi N, Wesolowska O, Michalak K. Interactions of phenothiazines with lipid bilayer and their role in multidrug resistance reversal. Curr Drug Targets 2006;7:1095-105
   PubMed Web of Science ®Google Scholar
• Jutila A, Soederlund T, Pakkanen AL, Comparison of the effects of clozapine, chlorpromazine, and haloperidol on membrane lateral heterogeneity. Chem Phys lipids 2001;112:151-63
   PubMed Web of Science ®Google Scholar
• Hendrich AB, Wesolowska O, Michalak K. Trifluoperazine induces domain formation in zwitterionic phosphatidylcholine but not in charged phosphatidylglycerol bilayers. Biochim Biophys Acta 2001;1510:414-25
   PubMed Web of Science ®Google Scholar
• Rosso J, Zachowski A, Devaux PF. Chlorpromazine induced changes in the lipid fluidity of erythrocyte cell membranes. Biochim Biophys Acta 1988;942:271-9
   PubMedGoogle Scholar
• Kohler T, Pechre JC, Plesiat P. Bacterial antibiotic efflux systems of medical importance. Cell Mol Life Sci 1999;56:771-8
   PubMed Web of Science ®Google Scholar
• Kaatz GW, Moudgal VV, Seo SM, Kristiansen JE. Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in staphylococcus aureus. Antimicrob Agents Chemother 2003;47:719-26
   PubMed Web of Science ®Google Scholar
• Lialiaris T, Pantazaki A, Sivridis E, Mourelatos D. Chlorpromazine-induced damage on nucleic acids: a combined cytogenetic and biochemical study. Mutat Res 1992;265:155-63
   PubMed Web of Science ®Google Scholar
• Hawtrey A, Joubert D, Van JP, Low concentrations of chlorpromazine and related phenothiazines stimulate gene transfer in HeLa cells via receptor-mediated endocytosis. Drug Deliv 2002;9:47-53
   PubMed Web of Science ®Google Scholar
• Viola G, Latterini L, Vedaldi D, Photosensitization of DNA strand breaks by three phenothiazine derivatives. Chem Res Toxicol 2003;16:644-51
   PubMed Web of Science ®Google Scholar
• Amaral L, Kristiansen JE. Phenothiazines: potential management of Creutzfeldt–Jacob disease and its variants. Int J Antimicrob Agents 2001;18:411-17
   PubMed Web of Science ®Google Scholar
• Miskolci C, Labadi I, Kurihara T, Guanine-cytosine rich regions of plasmid DNA can be the target in anti-plasmid effect of phenothiazines. Int J Antimicrob Agents 2000;14:243-7
   PubMed Web of Science ®Google Scholar
• Martins M, Viveiros M, Amaral L, SILA 421, an inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular extensively drug-resistant tuberculosis (XDR-TB). Int J Antimicrob Agents 2008;33:479-82
   Web of Science ®Google Scholar
• Martins M, Viveiros M, Amaral L. The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis. In Vivo 2007;21:771-6
   PubMed Web of Science ®Google Scholar
• Martins M, Schelz Z, Martins A, In vitro and ex vivo activity of thioridazine derivatives against mycobacterium tuberculosis. Int J Antimicrob Agents 2007;29:338-40
   PubMed Web of Science ®Google Scholar
• Amaral L, Boeree MJ, Gillespie SH, Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Int J Antimicrob Agents. 2010;35:524-6
   Google Scholar
• Abbate E, Vescoso M, Natiello M, Tuberculosis extensamente resistente (XDR-TB) en Argentina: aspectos destacbles epidemiologicos, bacteriologicos, terapeuticos y evolutivos. Rev Argent Med Respiratoria 2007;1:19-25
   Google Scholar